Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Expands By 1,923.2%

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the target of a significant growth in short interest during the month of August. As of August 31st, there was short interest totaling 15,579 shares, a growth of 1,923.2% from the August 15th total of 770 shares. Based on an average daily trading volume, of 17,581 shares, the days-to-cover ratio is currently 0.9 days. Currently, 0.9% of the shares of the company are sold short.

Hedge Funds Weigh In On Bolt Biotherapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nan Fung Group Holdings Ltd bought a new stake in shares of Bolt Biotherapeutics in the 2nd quarter worth approximately $19,250. Squarepoint Ops LLC increased its position in shares of Bolt Biotherapeutics by 19.8% during the third quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock valued at $79,000 after purchasing an additional 2,448 shares during the period. Shay Capital LLC bought a new stake in shares of Bolt Biotherapeutics during the third quarter valued at approximately $85,000. Susquehanna International Group LLP acquired a new position in shares of Bolt Biotherapeutics in the third quarter valued at $89,000. Finally, Nano Cap New Millennium Growth Fund L P bought a new position in Bolt Biotherapeutics in the fourth quarter worth $112,000. 86.70% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on BOLT. HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Bolt Biotherapeutics in a research report on Thursday, May 28th. Rodman & Renshaw initiated coverage on Bolt Biotherapeutics in a research report on Thursday, May 28th. They issued a “buy” rating and a $22.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Friday, July 17th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $14.50.

Bolt Biotherapeutics Stock Performance

Shares of Bolt Biotherapeutics stock traded up $0.05 during midday trading on Thursday, hitting $3.73. The company had a trading volume of 96,975 shares, compared to its average volume of 25,388. Bolt Biotherapeutics has a 1-year low of $3.13 and a 1-year high of $7.20. The business’s 50 day simple moving average is $3.87 and its two-hundred day simple moving average is $4.35. The stock has a market cap of $7.18 million, a PE ratio of -0.23 and a beta of 1.09. The company has a debt-to-equity ratio of 1.47, a current ratio of 2.61 and a quick ratio of 2.61.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($4.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.39) by ($1.18). The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.50 million. Bolt Biotherapeutics had a negative net margin of 611.47% and a negative return on equity of 126.23%. As a group, equities analysts predict that Bolt Biotherapeutics will post -11.1 EPS for the current fiscal year.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.